Details

Autor(en) / Beteiligte

• Bekeschus, Sander
• Eisenmann, Sebastian
• Sagwal, Sanjeev Kumar
• Bodnar, Yana
• Moritz, Juliane
• Poschkamp, Broder
• Stoffels, Ingo
• Emmert, Steffen
• Madesh, Muniswamy
• Weltmann, Klaus-Dieter
• von Woedtke, Thomas
• Gandhirajan, Rajesh Kumar

Titel

xCT (SLC7A11) expression confers intrinsic resistance to physical plasma treatment in tumor cells

Ist Teil von

• Redox biology, 2020-02, Vol.30, p.101423, Article 101423

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Cold physical plasma is a partially ionized gas investigated as a new anticancer tool in selectively targeting cancer cells in monotherapy or in combination with therapeutic agents. Here, we investigated the intrinsic resistance mechanisms of tumor cells towards physical plasma treatment. When analyzing the dose-response relationship to cold plasma-derived oxidants in 11 human cancer cell lines, we identified four ‘resistant’ and seven ‘sensitive’ cell lines. We observed stable intracellular glutathione levels following plasma treatment only in the ‘resistant’ cell lines indicative of altered antioxidant mechanisms. Assessment of proteins involved in GSH metabolism revealed cystine-glutamate antiporter xCT (SLC7A11) to be significantly more abundant in the ‘resistant’ cell lines as compared to ‘sensitive’ cell lines. This decisive role of xCT was confirmed by pharmacological and genetic inhibition, followed by cold physical plasma treatment. Finally, microscopy analysis of ex vivo plasma-treated human melanoma punch biopsies suggested a correlation between apoptosis and basal xCT protein abundance. Taken together, our results demonstrate that xCT holds the potential as a biomarker predicting the sensitivity of tumor cells towards plasma treatment. [Display omitted]